National Bank of Canada’s Eupraxia Pharmaceuticals EPRX Stock Holding History

National Bank of Canada’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36	Sell	8 -351	-98%	-$2.42K	﹤0.01%	3071
2026 Q1	$812	Sell	359 -227	-39%	-$1.83K	﹤0.01%	2697
2025 Q4	$4.44K	Sell	586 -296	-34%	-$1.82K	﹤0.01%	2454
2025 Q3	$5.03K	Buy	882 +152	+21%	+$827	﹤0.01%	2457
2025 Q2	$3.91K	Sell	730 -34	-4%	-$131	﹤0.01%	2535
2025 Q1	$2.49K	Buy	764 +721	+1,677%	+$2.49K	﹤0.01%	2476
2024 Q4	$135	Sell	43 -107	-71%	-$317	﹤0.01%	2779
2024 Q3	$394	Buy	+150	New	+$394	﹤0.01%	2495

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

National Bank of Canada's EPRX Position: Q2 2026 in Review

National Bank of Canada reduced its Eupraxia Pharmaceuticals (EPRX) stake by 98% in Q2 2026, selling an estimated $2.42K and leaving 8 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

National Bank of Canada first reported a position in EPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.03K in Q3 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

National Bank of Canada held 8 shares of Eupraxia Pharmaceuticals worth $36 as of Q2 2026.
National Bank of Canada sold 351 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $2.42K.
Eupraxia Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #3071 holding.
National Bank of Canada first reported a position in Eupraxia Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
National Bank of Canada's Eupraxia Pharmaceuticals position peaked at $5.03K in Q3 2025.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.